Merck KGaA

14 days ago · wsj.com

Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence Therapeutics, more than double the target's closing price as of Friday.

3 months ago · seekingalpha.com

Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript

3 months ago · zacks.com

Merck KGaA (MKKGY) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.57 per share a year ago.

3 months ago · businesswire.com

BAAR, Switzerland--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a new multi-year strategic collaboration to accelerate global clinical development with Merck KGaA, Darmstadt, Germany, a leading science and technology company. Merck KGaA, Darmstadt, Germany will adopt the end-to-end capabilities of the Evinova AI-Native platform covering all modules of study design, document authoring, and downstream automation to significantly reduce ti.

3 months ago · zacks.com

Merck KGaA (MKKGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

4 months ago · zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

4 months ago · zacks.com

Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 months ago · benzinga.com

Merck KGaA (OTC:MKKGY) (OTC:MKGAF) on Thursday agreed to acquire Bio-Techne Corporation (NASDAQ:TECH) in an all-cash transaction valued at approximately $11.3 billion, as the German science and technology company seeks to expand its presence across life science research, diagnostics, and bioprocessing markets.

4 months ago · barrons.com

Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.

4 months ago · reuters.com

Merck KGaA has ​agreed to acquire ‌biotech firm Bio-Techne Corp ​for $73 per ​share in cash, ⁠the German ​science and ​healthcare firm said in a statement ​on ​Thursday.